Results 251 to 260 of about 848,154 (350)
First Generation Proteolysis Targeting Chimeras (PROTACs) for the Treatment of Progeria
We report the first PROTACs designed to degrade progerin, introducing a novel therapeutic approach for progeria. The best compound, UCM‐18142, significantly reduces progerin levels and improves key disease phenotypes in patient‐derived cells and in the LmnaG609G/G609G mouse model, paving the way for new treatment strategies targeting the root cause of ...
Jon Macicior‐Michelena +5 more
wiley +1 more source
Commensal bacterial outer membrane protein A induces interleukin-22 production. [PDF]
Wang Y, Ngo VL, Zou J, Gewirtz AT.
europepmc +1 more source
Peptide dendrimer–based nanoplatform with mitochondria‐targeting capability was developed for synergistic chemo‐photothermal therapy. The system promotes efficient transcytosis, induces mitochondrial dysfunction, triggers immunogenic cell death (ICD), and enhance antitumor immunity by promoting dendritic cell maturation and T‐cell activation, resulting
Min Li +15 more
wiley +1 more source
Circulating Interleukin-22 in Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. [PDF]
Correia AF +6 more
europepmc +1 more source
Environmental cadmium exposure disrupts testicular homeostasis through a novel intercellular communication axis. Stressed Sertoli cells release extracellular vesicles carrying damage‐associated molecular patterns and mitochondrial fragments, which activate macrophages via TLR4/NF‐κB signaling.
Jianfeng Ma +17 more
wiley +1 more source
Liver and pancreatic-targeted interleukin-22 as a therapeutic for metabolic dysfunction-associated steatohepatitis. [PDF]
Sajiir H +25 more
europepmc +1 more source
Serum levels of interleukin‐22 and hepatitis
Sadahisa Okuhara +11 more
openalex +1 more source

